Aim
Clostridioides difficile infection worsens the outcome of older hospitalized patients; thus, its diagnosis is necessary for the nosocomial infection control. The standard diagnostic test's limited sensitivity for Clostridioides difficile infection, an enzyme immunoassay for Clostridioides difficile toxins, is of clinical concern. Glutamate dehydrogenase detection is usually tested combined with Clostridioides difficile toxins. However, the clinical significance of a positive glutamate dehydrogenase result is unclear. We evaluated the association between positive glutamate dehydrogenase results, in‐hospital mortality and hospital stay length among older patients with suspected Clostridioides difficile infection.
Methods
In this retrospective cohort study, we examined the data of patients who received antibiotics (except for Clostridioides difficile infection treatment) after admission and tested for Clostridioides difficile infection using an enzyme immunoassay for Clostridioides difficile toxins and glutamate dehydrogenase in a secondary care hospital located in a rural region with high aging rate, between 2015 and 2018.
Results
In total, 188 patients were included (83.5% of them aged >75 years). Glutamate dehydrogenase positivity was independently associated with in‐hospital mortality (adjusted odds ratio 2.19, 95% confidence interval 1.14–4.21) and hospital stay length (regression coefficient 16.0, 95% confidence interval 5.15–26.9). Clostridioides difficile toxin positivity was independently associated with hospital stay duration (regression coefficient 14.5, 95% confidence interval 0.04–29.1), unlike in‐hospital mortality.
Conclusions
Glutamate dehydrogenase was closely related to in‐hospital mortality and prolonged hospitalization compared with Clostridioides difficile toxin. Clinicians should not neglect glutamate dehydrogenase‐positive patients, even when they are Clostridioides difficile toxin‐negative, and consider them as having poor prognostic potential. Geriatr Gerontol Int 2020; 20: 1138–1144.